Projects per year
Search results
-
Active
A PHASE 1, OPEN-LABEL, MULTICENTER STUDY OF JANX007 IN SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Heyne, K. (Key Personnel), Miles, B. J. (Key Personnel), Satkunasivam, R. (Key Personnel), Singh, M. (Key Personnel) & Zhang, J. (Key Personnel)
10/17/24 → …
Project: Clinical Trial
-
IMPACT ON SURVIVAL OF FAITH-BASED SPIRITUAL CARE OR PSYCHOTHERAPY COMBINED WITH PALLIATIVE CARE VERSUS PALLIATIVE CARE ALONE IN PATIENTS WITH NON-CURATIVE MALIGNANCIES
Mai, H. P. (PI), Abdelrahim, M. (Key Personnel), Chang, J. C. (Key Personnel), Ganguly, S. (Key Personnel), Heyne, K. (Key Personnel), Mathur, S. (Key Personnel), Niravath, P. A. (Key Personnel), Pingali, S. R. (Key Personnel), Shah, S. (Key Personnel), Sun, K. (Key Personnel), Venta, L. A. (Key Personnel) & Zhang, J. (Key Personnel)
6/19/24 → …
Project: Clinical Trial
-
Fulvestrant Plus Abemaciclib With or Without Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
Chang, J. C. (PI), Heyne, K. (Key Personnel), Mai, H. P. (Key Personnel), Mathur, S. (Key Personnel), Niravath, P. A. (Key Personnel) & Sun, K. (Key Personnel)
7/15/21 → …
Project: Clinical Trial
-
Sample and Data Collection for Houston Methodist Cancer Center Research
Chang, J. C. (PI), Bernicker, E. H. (Key Personnel), Darcourt, J. (Key Personnel), Heyne, K. (Key Personnel), Niravath, P. A. (Key Personnel) & Singh, M. (Key Personnel)
4/9/20 → …
Project: Clinical Trial
-
ALLIANCE A221602: OLANZAPINEWITH ORWITHOUT FOSAPREPITANT FOR THE PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) IN PATIENTS RECEIVING HIGHLY EMETOGENIC CHEMOTHERAPY (HEC): A PHASE III RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
Darcourt, J. (PI), Bernicker, E. H. (CoI), Chang, J. C. (CoI), Geyer, C. E. (CoI), Heyne, K. (CoI) & Niravath, P. A. (CoI)
3/6/20 → 3/5/45
Project: Non Profit
-
CTSU - IRB SUBMISSIONA Phase III Trial To Evaluate The Efficacy Of The Addition Of Inotuzumab Ozogamicin (A Conjugated Anti-Cd22 Monoclonal Antibody) To Frontline Therapy In Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL.
Abdelrahim, M. (CoI), Bernicker, E. H. (CoI), Chang, J. C. (CoI), Heyne, K. (CoI), Niravath, P. A. (CoI), Singh, M. (CoI) & Zhang, J. (CoI)
3/6/20 → 3/5/45
Project: Non Profit
-
A phase III, multicenter, randomized, study of atezolizumab/placebo administered in combination with paclitaxel, carboplatin, and bevacizumab to patients with newly-diagnosed stage III or stage IV ovarian, fallopian tube, or primary peritoneal cancer
Kamat, A. A. (PI), Bernicker, E. H. (CoI), Darcourt, J. (CoI), Heyne, K. (CoI), Singh, M. (CoI), Suri, A. (CoI) & Zaid, T. (CoI)
3/13/18 → 3/12/43
Project: Non Profit
-
A RANDOMIZED PHASE III DOUBLE BLINDED PLACEBO CONTROLLED TRIAL OFASPIRIN AS ADJUVANT THERAPY FOR HER2 NEGATIVE BREAST CANCER: THE ABCTRIAL
Arentz, C. (PI), Abdelrahim, M. (CoI), Bernicker, E. H. (CoI), Chang, J. C. (CoI), Heyne, K. (CoI), Niravath, P. A. (CoI), Singh, M. (CoI) & Zhang, J. (CoI)
12/8/16 → 12/7/41
Project: Non Profit
-
EAY131 - Molecular Analysis for Therapy Choice (MATCH)
Bernicker, E. H. (PI), Chang, J. C. (CoI), Darcourt, J. (CoI), Heyne, K. (CoI), Kamat, A. A. (CoI), Pingali, S. R. (CoI) & Singh, M. (CoI)
9/20/16 → 9/20/41
Project: Federal Funding Agencies
-
Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers
Bernicker, E. H. (PI), Darcourt, J. (CoI) & Heyne, K. (CoI)
5/6/16 → 5/6/41
Project: Federal Funding Agencies
-
Stem Cell: Biomarkers Including Putative Stem Cells Markers in Human Breast Cancers
Chang, J. C. (PI), Heyne, K. (Key Personnel), Niravath, P. A. (Key Personnel), Singh, M. (Key Personnel) & Templeton, S. (Key Personnel)
3/20/14 → …
Project: Clinical Trial
-
Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study:A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with orwithout Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients withDefici
Abdelrahim, M. (PI), Bernicker, E. H. (CoI), Darcourt, J. (CoI), Heyne, K. (CoI) & Singh, M. (CoI)
3/1/14 → 2/28/39
Project: Non Profit
-
Not started
Phase III Trial of Docetaxel vs. Docetaxel and Radium-223 for Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Heyne, K. (Key Personnel), Singh, M. (Key Personnel) & Zhang, J. (Key Personnel)
Project: Clinical Trial
-
A151216 - Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery ALCHEMIST
Zhang, J. (PI), Heyne, K. (Key Personnel) & Singh, M. (Key Personnel)
Project: Clinical Trial
-
Neoadjuvant Combination Therapy of Lenvima® plus Transcatheter Arterial Chemoembolization (TACE) for Transplant-Eligible Patients with Large Hepatocellular Carcinoma
Abdelrahim, M. (PI), Connor, A. A. (Key Personnel), Ghobrial, R. M. (Key Personnel), Gibbs, J. M. (Key Personnel), Graviss, E. A. (Key Personnel), Gupta, N. (Key Personnel), Heyne, K. (Key Personnel), Kodali, S. (Key Personnel), Moore, L. W. (Key Personnel), Rizk, E. (Key Personnel), Saharia, A. (Key Personnel), Singh, M. (Key Personnel) & Victor, III, D. W. (Key Personnel)
Project: Clinical Trial
-
Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150kHz) Concomitant With Gemcitabine and Nab-paclitaxel for Front-line Treatment of Locally-advanced Pancreatic Adenocarcinoma
Abdelrahim, M. (PI), Chang, J. C. (Key Personnel), Heyne, K. (Key Personnel), Niravath, P. A. (Key Personnel), Singh, M. (Key Personnel) & Templeton, S. (Key Personnel)
Project: Clinical Trial
-
Beamion BCGC-1: A Phase Ib dose escalation and Phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) in combination with intravenous trastuzumab deruxtecan (T-DXd) or in combination with intravenous trastuzumab emtansine (T-DM1) for treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC)
Niravath, P. A. (PI), Abdelrahim, M. (Key Personnel), Chang, J. C. (Key Personnel), Heyne, K. (Key Personnel), Mai, H. P. (Key Personnel), Singh, M. (Key Personnel) & Sun, K. (Key Personnel)
Project: Clinical Trial
-
Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Zhang, J. (PI), Chang, J. C. (Key Personnel), Heyne, K. (Key Personnel), Niravath, P. A. (Key Personnel) & Singh, M. (Key Personnel)
Project: Clinical Trial
-
Acupuncture Trial
Niravath, P. A. (PI), Chang, J. C. (Key Personnel), Heyne, K. (Key Personnel), Mai, H. P. (Key Personnel), Singh, M. (Key Personnel) & Sun, K. (Key Personnel)
Project: Clinical Trial
-
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Abdelrahim, M. (Key Personnel), Heyne, K. (Key Personnel), Niravath, P. A. (Key Personnel) & Singh, M. (Key Personnel)
Project: Clinical Trial
-
Phase Ib Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, or Microsatellite Instability-High/Mismatch Repair
Zhang, J. (PI), Heyne, K. (Key Personnel) & Singh, M. (Key Personnel)
Project: Clinical Trial
-
A Phase 1/2 Study of BMS-986340 as Monotherapy and in Combination with Nivolumab in Participants with Advanced Solid Tumors
Abdelrahim, M. (PI), Heyne, K. (Key Personnel), Singh, M. (Key Personnel), Sun, K. (Key Personnel) & Zhang, J. (Key Personnel)
Project: Clinical Trial
-
Real-world experience with Tecentriq + Avastin for the treatment of hepatocellular carcinoma (HCC) in the US
Abdelrahim, M. (PI), Connor, A. A. (Key Personnel), Dacha, S. (Key Personnel), Esmail, A. (Key Personnel), Esnaola, N. F. (Key Personnel), Ghobrial, R. M. (Key Personnel), Graviss, E. A. (Key Personnel), Gupta, N. (Key Personnel), Heyne, K. (Key Personnel), Hobeika, M. J. (Key Personnel), Kloc, M. (Key Personnel), Kodali, S. (Key Personnel), Mobley, C. M. (Key Personnel), Moore, L. W. (Key Personnel), Noureddin, M. (Key Personnel), Rizk, E. (Key Personnel), Victor, III, D. W. (Key Personnel) & Xu, S. (Key Personnel)
Project: Clinical Trial
-
Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients
Zhang, J. (PI), Haque, W. M. (Key Personnel), Heyne, K. (Key Personnel), Shadle, K. M. (Key Personnel) & Singh, M. (Key Personnel)
Project: Clinical Trial
-
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients With Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative
Niravath, P. A. (PI), Butler, E. B. (Key Personnel), Chang, J. C. (Key Personnel), Farach, A. M. (Key Personnel), Haque, W. M. (Key Personnel), Heyne, K. (Key Personnel), Morgan, P. B. (Key Personnel) & Teh, B. S. (Key Personnel)
Project: Clinical Trial
-
PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2
Niravath, P. A. (PI), Chang, J. C. (Key Personnel), Heyne, K. (Key Personnel) & Singh, M. (Key Personnel)
Project: Clinical Trial
-
A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients With DCIS Following Breast Conserving Therapy
Templeton, S. (PI), Arentz, C. (Key Personnel), Chang, J. C. (Key Personnel), Darcourt, J. (Key Personnel), Dubrovsky, E. (Key Personnel), Haque, W. M. (Key Personnel), Heyne, K. (Key Personnel), Morgan, P. B. (Key Personnel), Niravath, P. A. (Key Personnel) & Singh, M. (Key Personnel)
Project: Clinical Trial
-
A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo
Niravath, P. A. (PI), Abdelrahim, M. (Key Personnel), Arentz, C. (Key Personnel), Chang, J. C. (Key Personnel), Heyne, K. (Key Personnel) & Singh, M. (Key Personnel)
Project: Clinical Trial
-
A Study to Assess the Antitumor Activity and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma
Abdelrahim, M. (PI), Chang, J. C. (Key Personnel), Heyne, K. (Key Personnel), Niravath, P. A. (Key Personnel), Singh, M. (Key Personnel) & Zhang, J. (Key Personnel)
Project: Clinical Trial
-
Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy
Zhang, J. (PI), Chan, E. Y. (Key Personnel), Gibbs, J. M. (Key Personnel), Heyne, K. (Key Personnel), Kim, M. P. (Key Personnel), Rudkovskaia, A. A. (Key Personnel) & Singh, M. (Key Personnel)
Project: Clinical Trial
-
LEAP-012 - MERCK (7902-012, Site No. 0784) Safety and Efficacy of Lenvatinib (E7080 / MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable / Non-metastatic Hepatocellular Carcinoma (MK-7902-012 / E7080-G000-318 / LEAP-012)
Kodali, S. (PI), Abdelrahim, M. (Key Personnel), Ghobrial, R. M. (Key Personnel), Gibbs, J. M. (Key Personnel), Heyne, K. (Key Personnel), Saharia, A. (Key Personnel) & Victor, III, D. W. (Key Personnel)
Project: Clinical Trial
-
Sample and Data Collection for Hematologic disorders section, Houston Methodist Cancer Center
Pingali, S. R. (PI), Ganguly, S. (Key Personnel), Heyne, K. (Key Personnel), Hu, C.-C. A. (Key Personnel), Jin, M. M. (Key Personnel), Rice, L. (Key Personnel), Shah, S. (Key Personnel), Yang, J. (Key Personnel), Yi, Q. (Key Personnel) & Zieske, A. W. (Key Personnel)
Project: Clinical Trial
-
Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy
Abdelrahim, M. (Key Personnel), Chang, J. C. (Key Personnel), Heyne, K. (Key Personnel), Niravath, P. A. (Key Personnel) & Singh, M. (Key Personnel)
Project: Clinical Trial